- |||||||||| Invanz (ertapenem) / Merck (MSD)
Trial completion, Phase classification, Trial completion date, Head-to-Head: Antibiotics for Klebsiella Liver Abscess Study (clinicaltrials.gov) - Aug 27, 2018 P4, N=152, Completed, Recruiting --> Completed | Phase classification: PN/A --> P4 | Trial completion date: Apr 2018 --> Jan 2018
- |||||||||| Invanz (ertapenem) / Merck (MSD)
Trial primary completion date, Head-to-Head: Antibiotics for Klebsiella Liver Abscess Study (clinicaltrials.gov) - Apr 14, 2017 P=N/A, N=152, Recruiting, Recruiting --> Completed Trial primary completion date: Aug 2015 --> Dec 2017
- |||||||||| Trial completion, Trial primary completion date: Prevalence of Colon Cancer in Pyogenic Liver Abscess (clinicaltrials.gov) - Mar 1, 2016
P4, N=62, Completed, Recruiting --> Completed | N=200 --> 244 | Trial primary completion date: Feb 2016 --> May 2016 Recruiting --> Completed | Trial primary completion date: Jun 2016 --> Feb 2016
- |||||||||| ceftriaxone / Generic mfg., moxifloxacin intravenous / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Moxifloxacin Versus Ceftriaxone in the Treatment of Primary Pyogenic Liver Abscess (clinicaltrials.gov) - Dec 5, 2015 P4, N=24, Completed, Recruiting --> Completed | Trial primary completion date: Jun 2016 --> Feb 2016 Recruiting --> Completed | N=48 --> 24 | Trial primary completion date: Apr 2012 --> Dec 2010
- |||||||||| Phase classification, Trial initiation date, Trial primary completion date: Post Marketing Surveillance Study To Observe Safety And Efficacy Of Eraxis (clinicaltrials.gov) - Aug 12, 2015
P=N/A, N=200, Active, not recruiting, Initiation date: Aug 2012 --> Apr 2012 Phase classification: P4 --> P=N/A | Initiation date: Mar 2012 --> Aug 2012 | Trial primary completion date: Jul 2015 --> Feb 2016
- |||||||||| Enrollment closed, Trial primary completion date: Post Marketing Surveillance Study To Observe Safety And Efficacy Of Eraxis (clinicaltrials.gov) - Apr 20, 2015
P4, N=214, Active, not recruiting, Phase classification: P4 --> P=N/A | Initiation date: Mar 2012 --> Aug 2012 | Trial primary completion date: Jul 2015 --> Feb 2016 Completed --> Active, not recruiting | Trial primary completion date: Mar 2014 --> Sep 2015
- |||||||||| Trial primary completion date: Prevalence of Colon Cancer in Pyogenic Liver Abscess (clinicaltrials.gov) - Apr 14, 2015
P4, N=62, Recruiting, Completed --> Active, not recruiting | Trial primary completion date: Mar 2014 --> Sep 2015 Trial primary completion date: Jun 2015 --> Jun 2016
- |||||||||| Trial completion, Trial primary completion date: Laparoscopic Management of Periappendicular Abscess (clinicaltrials.gov) - Sep 28, 2014
P2, N=60, Completed, Recruiting --> Completed | Trial primary completion date: Mar 2013 --> Jan 2014 Recruiting --> Completed | Trial primary completion date: Dec 2015 --> Aug 2014
- |||||||||| Trial completion, Enrollment change, Trial primary completion date: Post Marketing Surveillance Study To Observe Safety And Efficacy Of Eraxis (clinicaltrials.gov) - Jul 16, 2014
P4, N=214, Completed, Recruiting --> Completed | Trial primary completion date: Dec 2015 --> Aug 2014 Enrolling by invitation --> Completed | N=3000 --> 214 | Trial primary completion date: Jul 2014 --> Mar 2014
- |||||||||| Invanz (ertapenem) / Merck (MSD)
Trial initiation date, Head-to-Head: Antibiotics for Klebsiella Liver Abscess Study (clinicaltrials.gov) - Dec 1, 2013 P=N/A, N=152, Recruiting, N=100 --> 35 Initiation date: Jan 2013 --> Nov 2013
- |||||||||| Invanz (ertapenem) / Merck (MSD)
Enrollment open, Head-to-Head: Antibiotics for Klebsiella Liver Abscess Study (clinicaltrials.gov) - Dec 1, 2013 P=N/A, N=152, Recruiting, Initiation date: Jan 2013 --> Nov 2013 Not yet recruiting --> Recruiting
|